Outcomes-Based Contract By Harvard Pilgrim For Testing Could Be Model For Pharma
Executive Summary
Prenatal testing services provider IIlumina commits to fund study on whether cost of expanding use of test is offset by reduction in spending on traditional screening practices.
You may also be interested in...
Installment Payments For Gene Therapy; From Luxturna To Hemophilia
Novel reimbursement scheme allowing payers to spread out the cost of an expensive gene therapy over time may get test drive with Spark's Luxturna before being used for big-market treatments for hemophilia.
Gottlieb Defends Accelerated Approval, Scorns Access Limits By Payors
US FDA's accelerated approval pathway is more reliable and has better validated biomarkers than a decade ago, commissioner says, arguing coverage limits on AA products are not in the interest of public health.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.